Resumen
The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and related tetrazolyl compounds and includes a method of removing a protective group (e.g., triphenylmethane (trityl) protecting group) from an N-protected tetrazolyl compound using a Lewis acid in an inert solvent and in the presence of an alcohol (e.g., reacting an N-protected tetrazolyl compound with ZnCl<SUB>2</SUB> in the presence of an alcohol).
Reivindicaciones
What is claimed is: 1. A process for preparing candesartan cilexetil and related tetrazolyl compounds comprising: (i) removing a protective group from an N-protected tetrazolyl compound by solvolysis using a Lewis acid in an inert solvent and in the presence of an alcohol; and (ii) isolating said candesartan cilexetil and related tetrazolyl compounds. 2. The process of claim 1, wherein said protecting group is a triphenylmethane (trityl) protecting group. 3. The process of claim 1, wherein said Lewis Acid is at least one OfAlCl3, TiCl4, ZnBr2, ZnCl2 and combinations thereof. 4. The process of claim 1, wherein said Lewis acid is ZnCl2. 5. The process of claim 1, wherein the amount of said is Lewis Acid is approximately 1 to approximately 3 equivalents per mole of said N-protected tetrazolyl compound. 6. The process of claim 1, wherein the amount of said is Lewis Acid is approximately 1.5 equivalents per mole of said N-protected tetrazolyl compound. 7. The process of claim 1, wherein said inert solvent is at least one of toluene, tetrahydrofuran, acetone, methyl ethyl ketone and mixtures thereof. 8. The process of claim 1, wherein said alcohol is a lower alcohol having between 1 and 4 carbons. 9. The process of claim 1, wherein the amount of said alcohol is approximately 1 mole per mole of said N-protected tetrazolyl compound. 10. The process of claim 1, wherein the amount of said alcohol is approximately 2 to approximately 100 moles per mole of said N-protected tetrazolyl compound. 11. The process of claim 1 , wherein the amount of said alcohol is approximately 5 to approximately 50 moles per mole of said N-protected tetrazolyl compound. 12. The process of claim 1, further comprising at least one additional processing step. 13. The process of claim 12, wherein said at least one additional process step comprises at least one of an extraction step, a washing step, a concentration step, a crystallization step and a recrystallization step. 14. The process of claim 13, where said recrystallization step comprises recrystallizing from a mixture of water and a ketone. 15. The process of claim 14, wherein said ketone is acetone. 16. The process of claim 13, further comprising the step of purifying said isolated candesartan cilexetil and related tetrazolyl compounds by suspending said isolated candesartan cilexetil and related tetrazolyl compounds in at least one of an organic acetate solvent, an alcohol, a mixture of water and said alcohol and mixtures thereof. 17. The process of claim 16 wherein said organic acetate solvent is at least one of isopropyl acetate, ethyl acetate and mixtures thereof and wherein said alcohol is at least one of methanol, ethanol and mixtures thereof. 18. The process of claim 1, further comprising preparing l-[[(cyclohexyloxy) carbonyl]oxy]ethyl 2-ethoxy-l-[[2'-(l-triphenylmethyl-lH-tetrazol-5-yl)biphenyl-4- yl]methyl]-lH-benzimidazole-7-carboxylate (i.e., candesartan cilexetil trityl) as an intermediate by condensing 2-ethoxy-l-[[2'-(l-triphenylmethyl-lH-tetrazol-5-yl)biphenyl-4- yl]methyl]-lH-benzimidazole-7-carboxylic acid with chloroethyl cyclohexyl carbonate in at least one high-boiling organic solvent in the presence of potassium carbonate. 19. The process of claim 18, wherein said at least one high-boiling organic solvent comprises at least one of N-methyl-2-pyrrolidinone (NMP), dimethyl sulfoxide (DMSO) and mixtures thereof. 20. The use of candesartan cilexetil and related tetrazolyl compounds made according to the process of claim 1 to treat hypertension. 21. The use of candesartan cilexetil and related tetrazolyl compounds made according to the process of claim 1 to treat at least one circulatory disease. 22. The use of claim 21, wherein said at least one circulatory disease is at least one of heart failure, stroke, cerebral apoplexy, nephropathy and nephritis. 23. Formulations containing candesartan cilexetil and related tetrazolyl compounds made according to the process of claim 1. 24. The formulations of claim 23, where said candesartan cilexetil and related tetrazolyl compounds have an approximate particle size of D90 < approximately 25 [mu]m. 25. The formulations of claim 23, where said candesartan cilexetil and related tetrazolyl compounds have an approximate particle size of D50 < approximately 10 [mu]m. 26. The formulations of claim 23, where said candesartan cilexetil and related tetrazolyl compounds have an approximate particle size of D1O ≤ approximately 3 [mu]m. 27. Candesartan cilexetil and related tetrazolyl compounds having a specific surface area of approximately 1 to approximately 3 m<2>/g. 28. Formulations containing said candesartan cilexetil and related tetrazolyl compounds according to claim 27. 29. Candesartan cilexetil and related tetrazolyl compounds having less than approximately 0.1% by weight of residual solvent. 30. Formulations containing said candesartan cilexetil and related tetrazolyl compounds according to claim 29.
